Neurocrine Biosciences Inc. (NASDAQ:NBIX) finished Friday with an addition of $0.56 to close at $105.22, an upside of 0.54 percent. An average of 646,220 shares of common stock have been traded in the last five days. There was a gain of $3.59 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 816,900 shares traded, while the 50-day average volume stands at 764,956.
NBIX stock has increased by 9.57% in the last month. The company shares reached their 1-month lowest point of $94.16 on 07/14/23. With the stock rallying to its 52-week high on 01/06/23, shares of the company touched a low of $89.04 and a high of $129.29 in 52 weeks. It has reached a new high 4 times so far this year and lost -11.91% or -$14.22 in price. In spite of this, the price is down -18.62% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NBIX stock investors should be aware that Neurocrine Biosciences Inc. (NBIX) stock had its last reported insider trading activity 103 days ago on May 01. In this transaction, the insider spent $1,184,049. Director, RASTETTER WILLIAM H, disposed of 4,300 shares at a price of $101.43 on May 01. The insider now owns more than $436,135 worth of shares. Prior to that, Chief Human Resources Officer Cooke Julie went on to Sale 100 shares at $103.82 each on Apr 25. An amount of $10,382 was transacted.
Valuation Metrics
Neurocrine Biosciences Inc. (NBIX) has a trailing price-to-earnings (P/E) ratio of 60.47. The stock’s beta is 0.46. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.24, the price-to-book (PB) ratio at 5.54, and the price-to-cash flow ratio at 37.62.
Financial Health
The quick ratio of Neurocrine Biosciences Inc. for the three months ended June 29 was 2.50, and the current ratio was 2.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.09 for the quarter ending June 29. Neurocrine Biosciences Inc.’s EBITDA margin for the year ending June 29 is 17.89%, while its operating margin for the same period stands at 9.00%. Its gross profit as reported stood at $1.47 billion compared to revenue of $1.49 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Neurocrine Biosciences Inc.’s return on assets was 7.40%.
Earnings Surprise
For the three-month period that ended June 29, Neurocrine Biosciences Inc. had $816.5 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $95.5 million in the quarter, while revenues of -$76.6 million were grew 117.7%. The analyst consensus anticipated Neurocrine Biosciences Inc.’s latest quarter earnings to come in at $0.78 per share, but it turned out to be $0.95, a 21.80% surprise. For the quarter, EBITDA amounted to $78.9 million. Shareholders own equity worth $97.65 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Neurocrine Biosciences Inc. (NBIX) price momentum. RSI 9-day as of the close on 11 August was 72.28%, suggesting the stock is Overbought, with historical volatility in this time frame at 20.49%.
As of today, NBIX’s price is $102.75 +3.53% or $3.59 from its 5-day moving average. NBIX is currently trading +10.63% higher than its 20-day SMA and +8.24% higher than its 100-day SMA. However, the stock’s current price level is +17.52% above the SMA50 and -4.44% below the SMA200.
The stochastic %K and %D were 73.91% and 64.08%, respectively, and the average true range (ATR) was 2.38. With the 14-day stochastic at 86.56% and the average true range at 2.32, the RSI (14) stands at 68.63%. The stock has reached 0.85 on the 9-day MACD Oscillator while the 14-day reading was at 1.37.
Analyst Ratings
SVB Securities upgraded Neurocrine Biosciences Inc. (NASDAQ: NBIX) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as a Market perform. The consensus rating for Neurocrine Biosciences Inc. (NBIX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NBIX, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 16 others rate it as a “buy”.
What is NBIX’s price target for the next 12 months?
Analysts predict a range of price targets between $95.00 and $150.00, with a median target of $125.00. Taking a look at these predictions, the average price target given by analysts for Neurocrine Biosciences Inc. (NBIX) stock is $126.08.
